First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
Top Cited Papers
Open Access
- 7 September 2010
- Vol. 117 (2), 268-275
- https://doi.org/10.1002/cncr.25425
Abstract
BACKGROUND. Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS). METHODS. Patients with metastatic, well, or moderately differentiated pancreatic endocrine carcinomas who had not received prior systemic chemotherapy were treated with capecitabine (750 mg/m2 twice daily, days 1‐14) and temozolomide (200 mg/m2 once daily, days 10‐14) every 28 days. RESULTS. Among 30 patients treated, 21 (70%) patients achieved an objective radiographic response. Median progression‐free survival was 18 months. The rate of survival at two years was 92%. Only 4 patients (12%) experienced grade 3 or 4 adverse events. CONCLUSIONS. The combination of capecitabine and temozolomide is associated with an exceptionally high and durable response rate in metastatic endocrine carcinomas of the pancreas. Clinical endpoints, including response rate, survival, and toxicity, are superior to those observed with streptozocin‐based regimens Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine CarcinomasPancreas, 2009
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumorsEndocrine-Related Cancer, 2008
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine TumorsJournal of Clinical Oncology, 2006
- Endocrine tumours of the pancreasBest Practice & Research Clinical Gastroenterology, 2005
- Aggressive surgery for metastatic liver neuroendocrine tumorsSurgery, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaThe New England Journal of Medicine, 1992
- Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell CarcinomaThe New England Journal of Medicine, 1980
- TREATMENT OF MULTIPLE-HORMONE-PRODUCING MALIGNANT ISLET-CELL TUMOUR WITH STREPTOZOTOCINThe Lancet, 1968